This scientific paper discusses the effects of antidepressants, by use of a literature review.
Depression is among the most prevalent illnesses worldwide. Unfortunately, the response to pharmacological intervention is frequently ineffectual. Ketamine has been used in the application of brand-new glutamatergic drugs for the treatment of Treatment-Resistant Depression (TRD), as well as their alleged effectiveness mechanisms. About 30% of patients with depression do not respond well to psychotherapy or antidepressants. Although Electroconvulsive Therapy (ECT) is more effective at treating depression, its use is limited by adverse mental effects, and the likelihood of recurrent depression is higher. The prolonged use of antidepressants has been associated with side effects that have detrimental health consequences.
Furthermore, some antidepressants such as Ketamine and Esketamine have adverse effects on the human body. The purpose of this research was to establish whether Ketamine and Esketamine have significant health problems. Additionally, the research sought to answer the research question of whether the level of side effects has significance to determine the eradication of antidepressants to patients. The research concluded that the level of side effects of Ketamine and Esketamine is not significant to establish a serious health problem for depressant patients. Therefore, there is a pressing need to develop fresh treatment approaches for depression in general and focused interventions for depression.
Table of Contents
1. Abstract
2. Problem Statement
3. Literature Review and Discussion
4. Gaps in Research and Future Research Recommendations
5. Conclusion
Research Objectives and Themes
The primary objective of this research is to evaluate the safety and clinical impact of Ketamine and Esketamine, specifically investigating whether the associated side effects are significant enough to warrant limitations on their use in the treatment of depressive disorders.
- Efficacy and mechanism of action of glutamatergic drugs
- Clinical comparison of Ketamine and Esketamine side effects
- Impact of antidepressant use on suicidal ideation
- Review of current treatment-resistant depression protocols
- Evaluation of patient safety data following pharmacological intervention
Excerpt from the Book
Literature Review and Discussion
Most of Ketamine's antidepressant properties are thought to be caused by N-Methyl-D-aspartate (NMDA) receptor resistance and the drug's impact on glutamate neurotransmission. Evidence from research suggests that Esketamine may have a better therapeutic impact than Ketamine. Despite its effectiveness and safety not being established, Esketamine nasal spray is currently expensive and is not frequently used in the treatment of depression (Capuzzi et al., 2021). On the other hand, oral Ketamine is effective in treating depressive disorder.
The oral intake of Esketamine has been used in various studies despite slowed effectiveness. In Smith-Apeldoorn et al.(2022) the triple-blind randomized placebo-controlled trial was contrasted to daily oral Esketamine with placebo as with a combination of antidepressant treatment for six weeks, followed by four weeks of follow-up. Smith-Apeldoorn et al. (2022), depict that taking Ketamine orally is inconsistent and has low bioavailability.
Summary of Chapters
Abstract: Provides an overview of the prevalence of treatment-resistant depression and the need to investigate the side effects associated with Ketamine and Esketamine therapies.
Problem Statement: Outlines the clinical context of antidepressant use and the necessity of balancing therapeutic efficacy with potential negative health impacts.
Literature Review and Discussion: Examines the pharmacological mechanisms of Ketamine and Esketamine and discusses findings from various clinical trials regarding their effectiveness.
Gaps in Research and Future Research Recommendations: Identifies limitations in existing studies and calls for further research on long-term impacts and specific patient populations.
Conclusion: Summarizes that while side effects are present, they are not currently significant enough to discourage the use of these drugs, provided ethical and safety guidelines are followed.
Keywords
Depression, Ketamine, Esketamine, Antidepressants, Treatment-Resistant Depression, Pharmacology, Side Effects, Mental Health, Clinical Trial, Bioavailability, Suicidal Ideation, Glutamate, NMDA receptor, Patient Safety, Therapeutics
Frequently Asked Questions
What is the core focus of this research paper?
The paper examines the side effects and safety profile of Ketamine and Esketamine as treatments for depression, specifically for cases where traditional psychotherapy or standard antidepressants have failed.
What are the central themes discussed in the paper?
Key themes include the pharmacological efficacy of glutamatergic treatments, the trade-off between therapeutic benefits and adverse physical/mental side effects, and the risk of suicidal ideation.
What is the primary research question?
The central question is whether the side effects associated with Ketamine and Esketamine are significant enough to establish them as a serious health risk that would justify their removal as a treatment option.
Which scientific methodology is employed?
The research relies on a comprehensive literature review and analysis of existing quantitative data from peer-reviewed clinical trials, including randomized placebo-controlled studies.
How is the main body structured?
The body progresses from a formal definition of the problem to an in-depth review of existing literature, identification of research gaps, and a concluding evaluation of current study findings.
Which keywords define this document?
The work is defined by terms such as Treatment-Resistant Depression (TRD), Ketamine, Esketamine, pharmacology, clinical efficacy, and patient safety protocols.
Does the research address the potential for abuse?
Yes, the paper discusses the potential for misuse and the risk of increased suicidal thoughts, particularly in younger populations, and mentions the restricted distribution via the REMS program.
What is the author's conclusion regarding oral Esketamine?
The analysis indicates that oral intake of Esketamine often faces challenges such as slow effectiveness, inconsistency, and low bioavailability, which limits its standardized usage.
How is patient safety monitored during these treatments?
The study highlights that most research follows strict ethics and safety guidelines, using blinding in clinical trials to minimize bias and relying on peer-reviewed data to inform clinical recommendations.
- Citation du texte
- Rhoda Kariuki (Auteur), 2023, Effects of Antidepressants. A Literature Review, Munich, GRIN Verlag, https://www.grin.com/document/1361337
